ImmunityBio's 700% Revenue Boom Becomes Citadel's Latest I‑Told‑You‑So

Hedge funds don't need headlines to move — they need inflection points. ImmunityBio Inc (NASDAQ:IBRX) just delivered one. ImmunityBio stock has gone vertical, up nearly 96% year-to-date, but the real story isn't the stock move. It's the number behind it.Track IBRX stock here.On Thursday, ImmunityBio reported ~$113 million in 2025 revenue, marking a staggering 700% year-over-year increase — the kind of acceleration that turns early positioning into visible validation.The Revenue Inflection Hedge Funds Were P ...